Anuh Pharma Ltd
Anuh Pharma Ltd Q4 FY25 Results & Presentation Highlights: Revenue ₹198.14 Cr, PAT ₹12.46 Cr
Q4 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Anuh Pharma Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue difference). EBITDA for the quarter ended 31/03/2025: ₹20.07 Cr, a 27.61% increase QoQ; margin: 10.13%.
From Anuh Pharma Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue difference).
- Quarterly revenue grew 24.22% quarter-on-quarter, from ₹159.51 crore in Q3 FY 2025.
- The company reported its highest-ever quarterly revenue of ₹199.54 crore in Q4 FY 2025.
- Customer base increased from 698 to 737 in FY25; export customers grew from 260 to 304.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Manufacturing capacity expanded from 1,800 MT to 2,200 MT in FY25 to strengthen portfolio and market presence.
- Planned expansion of Intermediate manufacturing capacity by 300 MTPA in FY26 aimed at improving efficiency and supporting new product launches.
- Expect to add 5 to 6 new API products in FY26 to contribute to revenue growth and business expansion.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Anuh Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹202 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Themis Medicare Ltd (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q4 FY25 investor presentation — and how it ranks against sector p
- Lincoln Pharmaceuticals Ltd (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 investor presenta
- Kopran Ltd (Q4 FY25)
1,372 Lakhs (~7.37% decline) . Key investor presentation takeaways from Kopran Ltd's Q4 FY25 investor presentation — and how it ranks against sector peers.
- Fermenta Biotech Ltd (Q4 FY25)
Q4 FY25 Revenue: ₹143.7 crore . Key investor presentation takeaways from Fermenta Biotech Ltd's Q4 FY25 investor presentation — and how it ranks against sector
Frequently Asked Questions
What were Anuh Pharma Ltd Q4 FY25 results?
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue difference). EBITDA for the quarter ended 31/03/2025: ₹20.07 Cr, a 27.61% increase QoQ; margin: 10.13%.
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
Manufacturing capacity expanded from 1,800 MT to 2,200 MT in FY25 to strengthen portfolio and market presence.
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.